A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.

Date publication

mars 2018

Journal

Clinical therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Pivot X, Deslypere JP, Park LS, Kim MJ, Lee W, Lee J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29502805

Résumé

This first-in-human study of HD201 was designed to evaluate the pharmacokinetic (PK) equivalence between this biosimilar candidate and trastuzumab sourced in the European Union (EU-trastuzumab)*.

Mots clés

Herceptin, biosimilars, breast cancer, pharmacokinetics, trastuzumab

Référence

Clin Ther. 2018 Mar;40(3):396-405.e4